GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bionoid Pharma Inc (OTCPK:BINP) » Definitions » Operating Income

Bionoid Pharma (Bionoid Pharma) Operating Income : $-9.08 Mil (TTM As of Mar. 2011)


View and export this data going back to 2007. Start your Free Trial

What is Bionoid Pharma Operating Income?

Bionoid Pharma's Operating Income for the three months ended in Mar. 2011 was $-5.67 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2011 was $-9.08 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Bionoid Pharma's Operating Income for the three months ended in Mar. 2011 was $-5.67 Mil. Bionoid Pharma's Revenue for the three months ended in Mar. 2011 was $0.00 Mil. Therefore, Bionoid Pharma's Operating Margin % for the quarter that ended in Mar. 2011 was %.

Bionoid Pharma's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Bionoid Pharma's annualized ROC % for the quarter that ended in Mar. 2011 was -4,348.87%. Bionoid Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2011 was -181,536.00%.


Bionoid Pharma Operating Income Historical Data

The historical data trend for Bionoid Pharma's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bionoid Pharma Operating Income Chart

Bionoid Pharma Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10
Operating Income
-1.83 -0.92 -1.22 -2.93 -3.89

Bionoid Pharma Quarterly Data
Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.48 -0.70 -0.84 -1.87 -5.67

Bionoid Pharma Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Mar. 2011 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.08 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bionoid Pharma  (OTCPK:BINP) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Bionoid Pharma's annualized ROC % for the quarter that ended in Mar. 2011 is calculated as:

ROC % (Q: Mar. 2011 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2010 ) + Invested Capital (Q: Mar. 2011 ))/ count )
=-22.692 * ( 1 - -0.04% )/( (0.6 + 0.444)/ 2 )
=-22.7010768/0.522
=-4,348.87 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2011) data.

2. Joel Greenblatt's definition of Return on Capital:

Bionoid Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2011 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2011 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2010  Q: Mar. 2011
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-22.692/( ( (0.013 + max(-1.931, 0)) + (0.012 + max(-2.035, 0)) )/ 2 )
=-22.692/( ( 0.013 + 0.012 )/ 2 )
=-22.692/0.0125
=-181,536.00 %

where Working Capital is:

Working Capital(Q: Dec. 2010 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.05) - (1.898 + 0 + 0.083)
=-1.931

Working Capital(Q: Mar. 2011 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.057) - (1.973 + 0 + 0.119)
=-2.035

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2011) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Bionoid Pharma's Operating Margin % for the quarter that ended in Mar. 2011 is calculated as:

Operating Margin %=Operating Income (Q: Mar. 2011 )/Revenue (Q: Mar. 2011 )
=-5.673/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Bionoid Pharma Operating Income Related Terms

Thank you for viewing the detailed overview of Bionoid Pharma's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Bionoid Pharma (Bionoid Pharma) Business Description

Traded in Other Exchanges
N/A
Address
433 N Camden Dr, Beverly Hills, CA, USA, 90210
Bionoid Pharma Inc is a cannabis company that cultivates, extracts, tests, and distributes organic hemp, cannabinoid, and related products. Its products aid in decreasing pain, improving recovery time, enhancing performance, and enhance physical well-being.